InVision Medical Technology
Develops clinically-validated AI for echocardiography, streamlining interpretation, standardizing measurements, and surfacing undiagnosed disease. Founded and led by clinicians and computer scientists from Stanford and Cedars-Sinai. Backed by Y Combinator and strategic partners including Alexion, AstraZeneca Rare Disease, with live deployments through partners like HeartLab.
About InVision Medical Technology
At InVision, we use AI to help streamline the interpretation of ultrasounds and identify diseases that may have been missed by human readers. Our models have been tightly integrated into the clinical workflow to allow easy usage by clinicians. Our work has previously been peer-reviewed and published in several top medical venues, including Nature (2020), Nature Medicine (2021), Lancet Digital Health (2021), JAMA Cardiology (2022). Results from our blinded and randomized clinical trial on evaluating cardiac function have also been recently presented as a Late Breaking Clinical Trial at the European Society of Cardiology.
Products
Advanced image post-processing analysis software designed to aid diagnostic review, analysis, and reporting of echocardiographic DICOM images for cardiac function.
AI screening for cardiac amyloidosis, a rare, underdiagnosed, and now-treatable disease, from routine transthoracic echocardiography.
Opportunistic screening for cirrhosis and steatotic liver disease from the subcostal view captured during routine echocardiography.
Automated, structured echocardiographic reports built on two complementary open-source foundation models — EchoPrime and EchoNet-Measurements.
Multi-valve detection — mitral, tricuspid, and aortic — built on the same research foundation that produced the company's cleared products.
Removes both burnt-in and DICOM metadata PHI.
What customers say
“We aspire to prevent misdiagnosis of rare diseases, democratize expert knowledge to more clinicians, and ensure that excellent care is available to every patient — in every clinical setting.”
“We wanted a partner with real evidence — not a pilot in search of a publication. InVision arrived with the Nature paper, the FDA clearance, and a deployment plan. That's a different conversation.”
Security and compliance
As reported by InVision Medical Technology. Ask for audit reports before you buy.
- SOC 2Compliant
- ISO 9001Compliant
- HIPAACompliant
- FDA 510(k) Clearance — Precision LVEFCompliant
- FDA 510(k) Clearance — Precision Cardiac AmyloidCompliant
- FDA Breakthrough Device Designation — Precision Cardiac AmyloidCompliant
- FDA Breakthrough Device Designation — Precision CirrhosisCompliant
- FDA Total Product Lifecycle Advisory Program (TAP) — Precision Cardiac AmyloidCompliant
- CPT Category III code 0932T (effective January 1, 2025) — Precision Cardiac AmyloidCompliant
- DICOM Part 15 compliance — Automatic DICOM DeidentificationCompliant
- Session-only cookies (no persistent cookies)
- Commercially reasonable physical, managerial, and technical safeguards
- Security breach notification to affected users
- Third-party processors required to use reasonable confidentiality measures and comply with Privacy Policy
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Claim InVision Medical Technology